• Create account
  • Log in
Clinical Guidelines
  • Home
  • About
    • About the clinical guidelines
    • Declaring and dealing with competing interests
    • Frequently asked questions
    • Guideline journal articles
  • CCA guidelines
    • Barrett's Oesophagus
    • Bowel cancer
      • Colorectal cancer
      • Surveillance colonoscopy
    • Endometrial cancer
    • Cervical cancer screening
    • Lung cancer
      • Lung cancer prevention & diagnosis
      • Lung cancer treatment
    • Prostate cancer
      • Advanced prostate cancer
      • PSA testing
    • Sarcoma
    • Skin cancer
      • Melanoma
      • Keratinocyte cancer (non-melanoma)
    • Pain management
    • Archive of CCA guidelines
  • COSA guidelines
    • Adolescents and Young Adult (AYA) guidelines
      • AYA cancer fertility preservation
      • AYA early cancer detection
      • AYA psychosocial management
    • Cancer therapy medication safety
    • Gastroenteropancreatic neuroendocrine tumours
    • Head & neck cancer nutrition
    • Teleoncology
  • Hosted
    • Childhood Brain Tumour or Leukaemia
  • National Cancer Prevention Policy
  • View
  • View form
  • Code
  • History
  • Refresh
  • What links here
  • Related changes
  • Special pages
  • Permanent link
  • Page information
  • Browse properties

Citation:Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S 2013

From Cancer Guidelines Wiki
Jump to:navigation, search

Citation


Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013 May;143(5 Suppl):e437S-54S Available from: http://www.ncbi.nlm.nih.gov/pubmed/23649451.



Critical appraisals

  • Assign a critical appraisal


Compare quality appraisals for each clinical question

Cited by

  1. What are the optimal follow-up tests for people with lung cancer who have had curative intent treatment?
  2. What is the optimal model (provider) of care for the follow up of people with lung cancer who have had curative intent treatment?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Colt_HG,_Murgu_SD,_Korst_RJ,_Slatore_CG,_Unger_M,_Quadrelli_S_2013&oldid=155902"
Cancer Council would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.